Ironwood Pharmaceuticals has raised $50 million in a deal led by Morgan Stanley Investment Management and joined by many of its previous investors, the Cambridge, MA-based firm announced today. The company plans to use the cash to, among other things, help move its irritable bowel syndrome treatment linaclotide through Phase 3 clinical trials. Ironwood was founded a decade ago as Microbia by former Whitehead Institute researchers.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
